CY1111609T1 - Αγωγη υποκειμενων με χρονια νεφρικη νοσο (ckd) με τη χρηση ενωσεων λανθανιου - Google Patents

Αγωγη υποκειμενων με χρονια νεφρικη νοσο (ckd) με τη χρηση ενωσεων λανθανιου

Info

Publication number
CY1111609T1
CY1111609T1 CY20111100164T CY111100164T CY1111609T1 CY 1111609 T1 CY1111609 T1 CY 1111609T1 CY 20111100164 T CY20111100164 T CY 20111100164T CY 111100164 T CY111100164 T CY 111100164T CY 1111609 T1 CY1111609 T1 CY 1111609T1
Authority
CY
Cyprus
Prior art keywords
ckd
lanthanum
renal disease
subjects
treatment
Prior art date
Application number
CY20111100164T
Other languages
English (en)
Inventor
Raymond Dennis Pratt
Isobel Webster
Stephen Jp Damment
Original Assignee
Shire International Licensing B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37114439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111609(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire International Licensing B.V. filed Critical Shire International Licensing B.V.
Publication of CY1111609T1 publication Critical patent/CY1111609T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ένα υποκείμενο με συμπτώματα χρόνιας νεφρικής νόσου (CKD), που δεν βρίσκεται στο τελικό στάδιο της νεφρικής νόσου (ESRD), μπορεί να δεχθεί αγωγή με χορήγηση από το στόμα μιας φαρμακευτικής σύνθεσης με δραστικό συστατικό μια θεραπευτικώς αποτελεσματική ποσότητα μιας μη τοξικής ένωσης λανθανίου. Σε μια προτιμώμενη ενσωμάτωση, η σύνθεση περιέχει ένυδρο ανθρακικό λανθάνιο ή υδροξυανθρακικό λανθάνιο. Η χορήγηση μιας ένωσης λανθανίου μπορεί να παρεμποδίσει την πρόοδο της CDK, να υποβάλει σε θεραπευτική αγωγή την ασβεστοποίηση μαλακών ιστών, και να υποβάλει σε θεραπευτική αγωγή τον δευτεροπαθή υπερπαραθυρεο-ειδισμό.
CY20111100164T 2005-11-09 2011-02-11 Αγωγη υποκειμενων με χρονια νεφρικη νοσο (ckd) με τη χρηση ενωσεων λανθανιου CY1111609T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/272,563 US20070104799A1 (en) 2005-11-09 2005-11-09 Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
EP06012445A EP1785142B1 (en) 2005-11-09 2006-06-16 Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds

Publications (1)

Publication Number Publication Date
CY1111609T1 true CY1111609T1 (el) 2015-10-07

Family

ID=37114439

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100164T CY1111609T1 (el) 2005-11-09 2011-02-11 Αγωγη υποκειμενων με χρονια νεφρικη νοσο (ckd) με τη χρηση ενωσεων λανθανιου

Country Status (26)

Country Link
US (1) US20070104799A1 (el)
EP (1) EP1785142B1 (el)
JP (1) JP2009514986A (el)
KR (1) KR101318067B1 (el)
CN (1) CN101304753B (el)
AR (1) AR057876A1 (el)
AT (1) ATE492284T1 (el)
AU (1) AU2006311286B2 (el)
BR (1) BRPI0619667A2 (el)
CA (1) CA2629036C (el)
CY (1) CY1111609T1 (el)
DE (1) DE602006019043D1 (el)
DK (1) DK1785142T3 (el)
EA (1) EA015171B1 (el)
ES (1) ES2362201T3 (el)
HK (1) HK1102545A1 (el)
IL (1) IL190860A0 (el)
MY (1) MY147391A (el)
NO (1) NO20082536L (el)
NZ (1) NZ567519A (el)
PL (1) PL1785142T3 (el)
PT (1) PT1785142E (el)
SI (1) SI1785142T1 (el)
TW (1) TWI388329B (el)
WO (1) WO2007056721A2 (el)
ZA (1) ZA200804853B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2754696A1 (en) * 2009-05-15 2010-11-18 Natco Pharma Limited Process for the preparation of lanthanum carbonate dihydrate
US20110033529A1 (en) * 2009-08-06 2011-02-10 Durga Prasad Samantaray Oral pharmaceutical paricalcitol formulations
AU2011252915B2 (en) 2010-05-12 2016-05-19 Prokidney Bioactive renal cells
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
CN103127041A (zh) * 2012-02-23 2013-06-05 南京卡文迪许生物工程技术有限公司 含有醋酸镧的药物组合物及其制备方法和用途
CN103120654A (zh) * 2012-02-23 2013-05-29 南京卡文迪许生物工程技术有限公司 醋酸镧或其水合物治疗血磷酸盐过多症的用途
CN103127043A (zh) * 2013-03-07 2013-06-05 尹颖 一种稳定高效的降磷组合物
CN103127042A (zh) * 2013-03-07 2013-06-05 尹颖 一种稳定高效的降磷组合物
AU2020204692A1 (en) * 2019-01-04 2021-07-29 Nattopharma As Combination therapy of phosphate binders and vitamin K
CN111620363A (zh) * 2020-06-13 2020-09-04 南京卡文迪许生物工程技术有限公司 一种四水合碳酸镧的制备方法及其产品
CN111686008A (zh) * 2020-07-20 2020-09-22 温州海鹤药业有限公司 一种混煎中药去磷工艺

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0620728B1 (en) * 1992-01-13 1997-01-08 Pfizer Inc. Preparation of tablets of increased strength
CA2128199C (en) * 1994-07-15 1997-02-04 Bernard Charles Sherman Stable solid pharmaceutical compositions containing enalapril maleate
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
ATE499943T1 (de) * 2001-04-23 2011-03-15 Shire Int Licensing Bv Verwendung von lanthankarbonat zur prävention von nierensteinleiden
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
DE202004021169U1 (de) * 2003-08-26 2007-03-01 Shire Holdings Ag Pharmazeutische Formulierung, die Lanthanverbindungen enthält
AU2005269362B2 (en) * 2004-07-27 2010-08-12 Shire Pharmaceuticals, Inc. Method of treating hyperphosphataemia using lanthanum hydroxycarbonate
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
CA2601669A1 (en) * 2005-03-17 2006-09-28 Amgen Inc. Methods of decreasing calcification

Also Published As

Publication number Publication date
TW200727905A (en) 2007-08-01
CA2629036A1 (en) 2007-05-18
EA015171B1 (ru) 2011-06-30
KR101318067B1 (ko) 2013-10-15
US20070104799A1 (en) 2007-05-10
BRPI0619667A2 (pt) 2011-10-11
DK1785142T3 (da) 2011-03-14
AU2006311286B2 (en) 2012-08-23
EP1785142B1 (en) 2010-12-22
EP1785142A1 (en) 2007-05-16
AU2006311286A1 (en) 2007-05-18
ATE492284T1 (de) 2011-01-15
WO2007056721A3 (en) 2007-10-25
SI1785142T1 (sl) 2011-07-29
TWI388329B (zh) 2013-03-11
NZ567519A (en) 2011-04-29
HK1102545A1 (en) 2007-11-30
CN101304753B (zh) 2012-12-12
CN101304753A (zh) 2008-11-12
PL1785142T3 (pl) 2011-07-29
AR057876A1 (es) 2007-12-26
MY147391A (en) 2012-11-30
DE602006019043D1 (de) 2011-02-03
NO20082536L (no) 2008-07-28
JP2009514986A (ja) 2009-04-09
ES2362201T3 (es) 2011-06-29
ZA200804853B (en) 2014-01-29
CA2629036C (en) 2014-07-22
KR20080071175A (ko) 2008-08-01
WO2007056721A2 (en) 2007-05-18
PT1785142E (pt) 2011-03-23
IL190860A0 (en) 2008-11-03
EA200801274A1 (ru) 2008-10-30

Similar Documents

Publication Publication Date Title
CY1111609T1 (el) Αγωγη υποκειμενων με χρονια νεφρικη νοσο (ckd) με τη χρηση ενωσεων λανθανιου
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
BRPI0513603A (pt) uso de hidroxicarbonato de lantánio e composição farmacêutica
ES2505643T3 (es) Galectina para uso en el tratamiento del síndrome del ojo seco
EA200901211A1 (ru) Антигены белка с5 и их применение
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
AR051925A1 (es) Anticuerpos anti-ox4ol
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
CY1114608T1 (el) Θεραπειες συνδυασμου που περιλαμβανουν κινοξαλινη αναστολεα pι3k αλφα για χρηση στην θεραπεια του καρκινου
BRPI0416628A (pt) uso de compostos orgánicos
ES2530780T3 (es) Composiciones y métodos para el tratamiento de trastornos oculares
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
CL2007002667A1 (es) Uso de trastuzumab para la prevencion o reduccion de la metastasis en un paciente que padece de cancer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab.
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
BRPI0718523B8 (pt) Forma de dosagem, e, método para preparar a forma de dosagem
TNSN05234A1 (en) Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
CY1121865T1 (el) Οφθαλμολογικες συνθεσεις και η χρηση τους
CO5660275A2 (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
UY29995A1 (es) Uso de un antagonista de cb1 para tratar efectos secundarios y síntomas negativos de la esquizofrenia
DK1735296T3 (da) Materialer og fremgangsmåder til behandling af koagulationslidelser
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
CY1117959T1 (el) 24-norudca για την αγωγη αυτοανοσης ηπατιτιδας
EA201100255A1 (ru) 5-алкинилпиримидины